ArticleMethods in molecular biology (Clifton, N.J.)2025
Neuroimmune Consequences of L. monocytogenes Infection.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polyphenols Bioactive Metabolites, and Their Anti-Biofilm and Neuroprotective Potential.Foods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in antimicrobials and supportive therapy enable most individuals who acquire bacterial meningitis to survive the acute episode. Nonetheless, many survivors suffer neurocognitive complications, often caused by the host's response to central nervous system (CNS) infection. A key goal of investigating bacterial meningitis in the laboratory is to identify the fundamental drivers of pathologic neurocognitive outcomes. Antibiotic treatment models in which animals survive the initial infection allow investigators to study the long-term consequences of infection, as well as early host responses. The protocol described here mimics the clinical scenario of patients being treated for, and surviving, what would otherwise be a fatal Listeria monocytogenes infection. In this model, C57BL/6J mice are infected intraperitoneally with 2-3 LD50 L. monocytogenes. CNS invasion by bacteria and leukocyte influxes into the brain are typically detectable 48 h postinfection. At that time, mice are treated with ampicillin, the same antibiotic used for human infection. A 14-day course of antibiotics is used to eliminate L. monocytogenes from the brain and peripheral organs, as well as to clear it from the gastrointestinal tract. Treated mice can be observed and studied for an extended period of time to meet diverse experimental objectives, such as analyzing the kinetics of host neuroimmune responses, assessing neurocognitive outcomes, or evaluating the effects of therapeutic interventions on key physiological measurements.
Indexed as
Identifiers
40622526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.